Soclenicant

Soclenicant
Clinical data
Other names	BNC210; BNC-210; IW2143; IW-2143
Routes of; administration	Oral
Drug class	α7-Nicotinic acetylcholine receptor negative allosteric modulator
ATC code	None;
Legal status
Legal status	Investigational;
Pharmacokinetic data
Bioavailability	69.4% (rat)
Protein binding	70–88%
Elimination half-life	6.2 hours (rat)
Identifiers
	IUPAC name 6-((2,3-dihydro-1H-inden-2-yl)amino)-1-ethyl-3-(4-morpholinylcarbonyl)-1,8-naphthyridin-4(1H)-one;
CAS Number	1020634-41-6 ;
PubChem CID	24772165;
UNII	QP49AY37OY;
Chemical and physical data
Formula	C24H26N4O3
Molar mass	418.497 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN1C=C(C(=O)C2=C1N=CC(=C2)NC3CC4=CC=CC=C4C3)C(=O)N5CCOCC5;
	InChI InChI=1S/C24H26N4O3/c1-2-28-22-19-7-3-4-8-20(19)24(30)27-23(22)26-21-13-14-15-16-17-21/h3-8,13-17,26H,2,9-12H2,1H3; Key:XYCMUJUHXRZPMP-UHFFFAOYSA-N;

Soclenicant (INNTooltip International Nonproprietary Name), also known by its developmental code names BNC210 and IW-2143, is an antinicotinic agent which is under development for the treatment of anxiety disorders such as social phobia and generalized anxiety disorder, as well as for treatment of agitation, post-traumatic stress disorder (PTSD), and depressive disorders. It is taken by mouth.

The drug acts as a highly selective negative allosteric modulator (NAM) of the α₇-nicotinic acetylcholine receptor (α₇-nAChR). It produces anxiolytic-, anti-stress-, and antidepressant-like effects without causing sedation, memory or motor impairment, or physical dependence in rodents. Chemically, soclenicant is a synthetic heterocyclic small-molecule compound based on a 1,8-naphthyridin-4-one scaffold, bearing amide and amine functionalities.

Soclenicant is being developed by Bionomics. It has also been developed by Ironwood Pharmaceuticals and EmpathBio. Bionomics was acquired by Neuphoria Therapeutics in December 2024. As of December 2024, soclenicant is in phase 3 clinical trials for anxiety disorders, phase 2 trials for agitation and PTSD, and no recent development has been reported for depressive disorders. The drug received Fast Track designation from the United States Food and Drug Administration (FDA) in 2019. It was first described in the literature, in a conference abstract, by 2007.